Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Functional Connectivity as an Early Marker of Indication for Deep Brain Stimulation Treatment in Parkinson’s Disease
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
160
The aim of this study was to identify early neuroimaging predictive biomarkers of the need for deep brain stimulation (DBS) use in patients with Parkinson’s Disease (PD).

DBS has become a well-established neuromodulating treatment for PD. Its therapeutic benefits still vary among PD patients. This variability could depend several features, but also on having the correct clinical indication to DBS. Biomarkers that predict indication to DBS treatment and its clinical response are still largely lacking.
PD patients performed clinical and cognitive evaluations and resting-state functional MRI (RS-fMRI) at baseline and every year for 4 years. Patients were divided into two groups: 19 patients eligible for DBS (PD-DBS) over 48 months and 41 patients who did not meet the criteria to undergo DBS surgery (PD-noDBS). 60 age- and sex-matched controls performed baseline assessments. Graph analysis and connectomics assessed global and local topological network properties and regional functional connectivity (FC) at baseline and changes over-time.

Lobar network analysis showed a significant higher mean nodal strength, local efficiency and clustering coefficient of the occipital areas in PD-DBS relative to both controls and PD-noDBS at baseline. These results were then confirmed by regional analysis. A significant increased FC between basal ganglia and frontal/sensorimotor networks was found in PD-noDBS compared to both controls and PD-DBS patient at baseline. Referring to longitudinal analysis, PD-DBS patients showed a progressive decreased FC within occipital and between occipital and parietal networks compared to PD-noDBS (stable over time). Progressive decreased FC between frontal and basal ganglia networks occurred in PD-noDBS relative to PD-DBS (stable over time). Functional alterations within occipital network were positively related to tremor in PD-DBS patients at baseline and over time.

RS-fMRI analysis might represent an early biomarker that help clinicians to establish the correct indication for DBS in PD patients.
Authors/Disclosures
Luigi Albano, MD (IRCCS San Raffaele and Vita-Salute San Raffaele University)
PRESENTER 		Luigi Albano has nothing to disclose.
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Silvia Basaia Silvia Basaia has nothing to disclose.
Camilla Cividini, MSc (San Raffaele Scientific Institute, Vita-Salute San Raffaele University) Ms. Cividini has nothing to disclose.
No disclosure on file
Iva Stankovic (Neurology Clinic, Clinical Center of Serbia, University of Belgrade) Iva Stankovic has nothing to disclose.
Alexandra Tomic No disclosure on file
Elka Stefanova No disclosure on file
Vladana Markovic No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of Â鶹´«Ã½Ó³»­, Science and Technological Development of Serbia.
Massimo Filippi, MD, FÂ鶹´«Ã½Ó³»­ (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.